Study on sedative effect and safety of dexmedetomidine nasal spray for painless fiberoptic bronchoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400092233

Enrollment

Unknown

Registered

2024-11-12

Start date

2025-01-01

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory disease

Interventions

Control group :0.9% Sodium Chloride Injection

Dextrmedetomidine nasal spray group:Dextrmedetomidine nasal spray

Lidocaine spray group:Lidocaine spray

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 75 years, classified as American Society of Anesthesiologists (ASA) Physical Status Class I to III, undergoing painless bronchoscopy

Exclusion criteria

Exclusion criteria: 1. Individuals with a history of allergies to propofol, dexmedetomidine, lidocaine, and opioid drugs, as well as a history of mental illness. 2. Patients with severe hepatic and renal dysfunction, among other organ impairments. 3.Exclusion Criteria: Patients who required conversion to laryngeal mask airway (LMA) placement during surgery.

Design outcomes

Primary

Measure	Time frame
Sedative effect;Respiratory Function;Circulation;	—

Secondary

Measure	Time frame
Coughing cough;nausea and vomiting;	—

Countries

China

Contacts

Public ContactLini Chen

The Second Affiliated Hospital of Guangxi Medical University

906898932@qq.com+86 180 7092 7318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026